Jung Ha Park1,2, Ju Young Kim1, Jong Han Choi3,4, Hye Soon Park5, Hyun-Young Shin6, Jae Min Lee7, Jin-Wook Kim8,9, Hae-Jin Ko10, Suk Chon11, Bu Kyung Kim12, Chul Sik Kim13, Soo Lim14. 1. Department of Family Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 2. Department of Family Medicine, Jeju National University Hospital, Jeju, South Korea. 3. Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 4. Department of Internal Medicine, Konkuk University School of Medicine, Konkuk University Medical Center, Seoul, South Korea. 5. Department of Family Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. 6. Department of Family Medicine, College of Medicine, Hanyang University, Myongji Hospital, Goyang, South Korea. 7. Daejeon Endo Internal Medicine Clinic, Daejeon, South Korea. 8. Department of Family Medicine, Obesity and Metabolic Disease Center, Seongnam Central Hospital, Seongnam, South Korea. 9. Department of Family Medicine, CHAUM Medical Check-Up Center, CHA Bundang Medical Center, CHA University, Seongnam, South Korea. 10. Department of Family Medicine, School of Medicine, Kyungpook National University, Kyungpook National University Hospital, Daegu, South Korea. 11. Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Kyung Hee University Hospital, Seoul, South Korea. 12. Department of Internal Medicine, Kosin University College of Medicine, Busan, South Korea. 13. Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, South Korea. 14. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. limsoo@snu.ac.kr.
Abstract
OBJECTIVE: We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea. METHODS: People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values. RESULTS: The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m2, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m2 at 2 months; -4.23 kg and -1.55 kg/m2 at 4 months, and -5.14 kg and -1.89 kg/m2 at 6 months (all P < 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%). CONCLUSIONS: In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.
OBJECTIVE: We investigated the efficacy and safety of liraglutide 3 mg daily in combination with diet and exercise 2, 4, and 6 months after initiation in real-world settings in Korea. METHODS: People first using liraglutide starting in 2018 were recruited from ten sites in Korea. Body weight and body mass index (BMI) were measured after 2, 4, and 6 months and compared with baseline values. RESULTS: The full cohort comprised 769 participants: 672 in the 2-month group, 427 in the 4-month group, and 219 in the 6-month group. The baseline mean ± standard deviation of BMI and body weight were 32.2 ± 5.1 kg/m2, and 87.5 ± 18.8 kg, respectively. Body weight and BMI decreased after initiation of liraglutide treatment: -2.94 kg and -1.08 kg/m2 at 2 months; -4.23 kg and -1.55 kg/m2 at 4 months, and -5.14 kg and -1.89 kg/m2 at 6 months (all P < 0.001). In the 6-month cohort, 52.5% and 18.3% of subjects lost ≥5% and ≥10% of body weight, respectively. After 6 months, systolic and diastolic blood pressure decreased significantly by 3.90 and 1.93 mmHg, respectively. In those with diabetes mellitus, HbA1c and fasting glucose levels decreased significantly by 1.14% and 27.8 mg/dl, respectively. Among all participants, 27.6% experienced adverse effects, including nausea (20.8%), vomiting (5.2%), diarrhoea (2.5%), and skin rash (3.6%). Documented reasons for discontinuation of treatment were lack of effect (4.4%), adverse events (4.3%), and high cost (3.1%). CONCLUSIONS: In real-world settings in Korea, daily treatment with liraglutide 3 mg was associated with clinically meaningful weight loss without serious adverse events.
Authors: Tina Vilsbøll; Milan Zdravkovic; Tu Le-Thi; Thure Krarup; Ole Schmitz; Jean-Pierre Courrèges; Robert Verhoeven; Ingrid Bugánová; Sten Madsbad Journal: Diabetes Care Date: 2007-03-19 Impact factor: 19.112
Authors: Xavier Pi-Sunyer; Arne Astrup; Ken Fujioka; Frank Greenway; Alfredo Halpern; Michel Krempf; David C W Lau; Carel W le Roux; Rafael Violante Ortiz; Christine Bjørn Jensen; John P H Wilding Journal: N Engl J Med Date: 2015-07-02 Impact factor: 91.245
Authors: Gretchen A Stevens; Gitanjali M Singh; Yuan Lu; Goodarz Danaei; John K Lin; Mariel M Finucane; Adil N Bahalim; Russell K McIntire; Hialy R Gutierrez; Melanie Cowan; Christopher J Paciorek; Farshad Farzadfar; Leanne Riley; Majid Ezzati Journal: Popul Health Metr Date: 2012-11-20
Authors: Sean Wharton; Aiden Liu; Arash Pakseresht; Emil Nørtoft; Christiane L Haase; Johanna Mancini; G Sarah Power; Sarah Vanderlelie; Rebecca A G Christensen Journal: Obesity (Silver Spring) Date: 2019-05-07 Impact factor: 5.002
Authors: Gerardo Calderon; Daniel Gonzalez-Izundegui; Kuangda L Shan; Oscar A Garcia-Valencia; Lizeth Cifuentes; Alejandro Campos; Maria L Collazo-Clavell; Meera Shah; Daniel L Hurley; Haitham S Abu Lebdeh; Mayank Sharma; Kristine Schmitz; Matthew M Clark; Karen Grothe; Manpreet S Mundi; Michael Camilleri; Barham K Abu Dayyeh; Maria D Hurtado Andrade; Mohamad A Mokadem; Andres Acosta Journal: Int J Obes (Lond) Date: 2021-11-22 Impact factor: 5.095
Authors: Liesbet Trenson; Sander Trenson; Falco van Nes; Carolien Moyson; Matthias Lannoo; Ellen Deleus; Ann Meulemans; Christophe Matthys; Ann Mertens; Bart Van der Schueren; Roman Vangoitsenhoven Journal: Obes Facts Date: 2021-11-22 Impact factor: 3.942